KnowTheStock
Log inCreate free account

CERUS CORP

CERS
Surgical & Medical Instruments & Apparatus · Nasdaq
$2.47last close · market cap 498.08 Million
Compare with…
32.5SCORE / 100
Our verdictSELLWeak Growth, Stock Price Very HighQtr Ending 2026-09-30

Why Sell

Balance sheet is moderate; income statement and cash flow are weak.

Next earnings: 2026-11-02 (AMC), EPS Forecast: ($0.01)

What is strong
  • Revenue Growth is 13.77%
  • Total Debt to Total Assets Ratio is 0.31
What to watch
  • Operating Income is Negative but improving
  • Net Income is Negative but improving
  • Earnings Per Share (EPS) is Negative but improving
  • Net Margin is -3.04%
  • Current Asset to Current Liability Ratio is 1.96
  • Debt Ratio is 0.63
  • Current Debt to Net Income Ratio not available
  • Cash from Operations is Negative
  • Capital Expenditure not available
  • Net Increase in Cash is Negative
  • Investment Risk is High

What changed

Score by quarter

Rated Sell for the last 12 quarters. This quarter: +0.7.

203040Sep 2018Sep 2026

What the score is made of

Income statement29.0 +4.4
Balance sheet52.3 +1.2
Cash flow7.7 -13.3

Change vs previous quarter.

Key numbers · latest quarter

Revenue (TTM)254.23 Million13.77 % growth
EPS0.00
Profit margin-3.04 %Profit per $1 of sales
P-E ratio—Not available
Market cap498.08 MillionShares × price
Debt-equity ratio0.84Leverage
Dividend0.00Per share, annual
Next earnings2026-11-02AMC · EPS forecast ($0.01)
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.

About CERUS CORP

cerus corporation is a biomedical products company focused on commercializing the intercept blood system to enhance blood safety. the intercept system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. the nucleic acid targeting mechanism of action enables intercept treatment to inactivate established transfusion threats, such as hepatitis b and c, hiv, west nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. cerus currently markets and sells the intercept blood system for both platelets and plasma in europe, russia, the middle east and selected countries in other regions around the world. the intercept red blood cell system is in clinical development.

CEO
William Greenman
Employees
406
Exchange
Nasdaq
cerus.com

Similar stocks

Loading…